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Background: Hepatitis B virus (HBV) reactivation can be asymptomatic 
or manifest as fatal fulminant hepatitis. Most international guidelines 
recommend screening patients prior to immunosuppressive therapy.
Aims: To determine HBV screening rates and modalities in patients 
receiving chemotherapy at the American University of Beirut Medical 
Center. 
Methods: A retrospective cohort review of electronic health records of 
adult patients who received chemotherapeutic agents, between June 
2015 and June 2016. Patients clinical characteristics were documented. 
Adequate screening was defined as performing all: HBsAg, HBs Abs, 
and anti HBc Abs (total). 
Results: A total of 1547 patients were initially assessed. 45.6% were 
males with a mean age of 56. 382 (30%) had hematologic malignan-
cies, of whom 111 underwent HSCT. Of those included, 303 (24%) 
patients were screened by at least one test for HBV and 42 (3.3%) 
for HBsAg, anti HBc Abs and HBs Abs. 
Patients who were appropriately screened were significantly younger 
(p=0.008) and more likely to have hematologic malignancies (n=35, 
83.3%, p<0.0001). Among patients with hematologic malignancies, 
appropriately screened patients (n=35) were younger (p=0.042) and 
had a history of HSCT (n=19, 54.3%, p=0.001).
Conclusion: Rates of screening for HBV prior to chemotherapy at our 
medical center are low, and not always complete or adequate. There 
is an urgent need to implement a better screening policy. 
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Introduction 
The global burden of hepatitis B virus (HBV) infec-
tion has been increasingly recognized. Viral hepati-
tis B and C are associated with significant morbidity 
and mortality [1]. Chronic HBV infection affects 6% 
of the world’s population [2]. It caused 686 000 
deaths in 2013, placing it among the 20 most com-
mon causes of mortality worldwide [3]. Endemicity 
varies worldwide between <2% and >8% (low and 
high, respectively [4]. In the Middle East, Lebanon 
is considered to be of moderate endemicity along 
with Turkey and Pakistan, while Saudi Arabia and 
Jordan are highly endemic for HBV infection [5, 6]. 
The pool of immunocompromised patients is 
ever increasing and it encompasses patients recei-
ving chemotherapy and anti-CD20 monoclonal an-
tibodies for neoplastic disorders, organ and bone 
marrow transplantation, those on chronic steroid 
therapy, and those on biological agents such as 
anti-tumor necrosis factor (anti-TNF).
In immunocompetent hosts, HBV infection usually 
causes acute hepatitis that resolves spontaneously 
in most patients. This results in HBsAg seronegati-
vity with persistently detectable antibodies against 
hepatitis B core antigen (anti-HBc) and/or against 
Hepatitis B surface antigen (anti-HBs). Despite that, 
HBV DNA can persist for years in hepatocytes, 
allowing the virus to replicate in certain immuno-
suppressive conditions [7]. The risk of reactivation 
depends greatly on the type of immunosuppressive 
agent used. Clinically, reactivation can be asymp-
tomatic or may cause fatal fulminant hepatitis. It 
typically occurs in patients with detectable HBsAg, 
and less frequently in those with resolved infection 
(negative HBsAg with positive anti-HBc and/or anti-
HBs) [8].
The incidence of reactivation in patients sero-
positive for HBsAg receiving rituximab can be as 
high as 59-80% [9]. Meanwhile, liver failure rates 
in patients with positive HBsAg and anti-HBc, who 
received chemotherapy, can reach 13.9% [10].
The US Food and Drug Administration (FDA) in-
cluded HBV reactivation in the boxed warning of 
anti-CD20 monoclonal antibodies in 2013, and re-
commends screening for HBV before administra-
tion of the drug [11]. HBV reactivation is diagnosed 
when reverse seroconversion from a negative to a 
positive HBsAg (in patients with positive anti-HBc) 
or when HBV DNA increases from the baseline. A 
rise in serum aminotransferases usually follows, in-
dicating a hepatitis flare [12].
One study performed in Egypt screened children 
receiving chemotherapy for hematological malig-
nancies, and concluded that 79% of them had de-
tectable HBsAg and/or HBV DNA levels, of whom 
70% developed viral reactivation [13].
HBV screening was shown to be cost-effective 
in cancer patients prior to rituximab (an anti-CD20) 
and chemotherapy, specifically in the case of hema-
topoietic stem cell transplantation [14]. Therefore, all 
patients who are anticipated to receive immunosup-
pressive therapy should be screened to assess their 
risk of reactivation. Screening should include chec-
king for serum HBV markers (HBsAg, anti-HBc, and 
possibly anti-HBs). Individuals with positive serology 
need to have their HBV DNA levels determined and 
antiviral prophylaxis initiated to minimize risk of re-
activation. [15].
Despite the increasing rate of HBV screening prior 
to immunosuppression, it remains suboptimal rea-
ching 28% even in patients at risk for acquiring HBV 
[16], and 70% in patients with non-Hodgkin lym-
phoma who are planned to receive anti-CD20 [17]. 
Screening recommendations
Various scientific bodies strongly recommend scree-
ning for hepatitis B for all cancer patients before 
chemotherapy and prophylactic interventions. The 
American Association for the Study of Liver Diseases 
(AASLD) and the Asian Pacific Association for the 
Study of the Liver (APASL) recommend testing for 
HBsAg and anti-HBc (IgG or total antibodies). Anti-
HBs antibodies can also be helpful but their role is 
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not well established [12, 18]. Screening should in-
clude all three serologic tests (HBsAg, anti-HBc and 
anti-HBs) according to the recent European Associa-
tion for the Study of the Liver (EASL) guidelines [19] 
and the Center for Disease Control (CDC) [20]. The 
American Gastroenterological Association (AGA) 
recommends testing for HBsAg and anti-HBc and 
HBV DNA quantitation if any of the serologic tests 
was positive in moderate and high risk patients (14). 
The American Society of Clinical Oncology (ASCO) 
recommends screening all patients before starting 
anti-CD20 therapy and before hematopoietic stem 
cell transplantation (high risk for reactivation), and 
patients at risk for acquiring HBV infection (being 
born in a country where the prevalence of HBV is 
greater than 2%, having sexual contact or living 
with a person who is HBV infected, IV drug users, 
those with HIV infection, and patients with high risk 
behaviors) prior to chemotherapy. Testing should in-
clude HBsAg and anti-HBc IgG antibodies [21].
Whenever HBsAg is positive, antiviral therapy is 
indicated before but without delaying cancer the-
rapy. In case of HBsAg negativity and anti-HBc po-
sitivity, clinicians can initiate antiviral prophylaxis in 
patients at high risk for reactivation, or can mo-
nitor for reactivation by checking HBV DNA and 
ALT every 3 months while on chemotherapy, then 
starting antiviral therapy at the first sign of reactiva-
tion [21]. Despite all the available recommendations, 
screening for HBV before initiating chemotherapy 
and immunosuppressant remains suboptimal. 
This study aims to evaluate the screening rates 
for HBV in a leading tertiary care university medi-
cal center in the Middle East, in patients receiving 
chemotherapy. 
Materials and methods 
Study design 
The study is a retrospective cohort review of the 
electronic health records (EHR) of patients who re-
ceived cancer chemotherapy or hematopoietic stem 
cell transplantation between June 2015 and June 
2016. Data was collected electronically, and was 
saved in a confidential file that only the PI and the 
Co-investigator have access to. The information re-
trieved included patients demographics, underlying 
medical conditions, indication for chemotherapy, 
and date of treatment initiation. Data about HBV 
screening, if done, was recorded after searching all 
the patients laboratory tests performed (since the 
date of their first encounter until the year 2017), and 
the type of serological tests done for screening. The 
Institutional Review Board (protocol number IM.AR-
B.13) approved the study protocol beforehand.
Patient population
The inclusion and exclusion criteria are iterated 
herein:
Inclusion Criteria:
- Patients older than 18 years
- Patients who received chemotherapy 
- Hematopoietic stem cell transplant recipients 
Exclusion Criteria:
- Patients with known Hepatitis B infection
Study endpoints
Primary endpoint: the percentage of patients who 
were screened
Secondary endpoint: the adequacy of screening
Statistical analysis
Descriptive analysis was performed. Percentages (%) 
were used for qualitative valuables and measures of 
central tendency (mean) were used for quantitati-
ve variables. Comparisons were made and variables 
associated with appropriate hepatitis B screening 
were assessed using chi-square test for categorical 
variables and t-test for continuous variables. Multi-
variate logistic regression analysis was used to ad-
just for potentially confounding variables. The data 
was analyzed using statistical software SPSS.
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Table 2.  Hepatitis B screening rates according to 








n=888 n=1270HSCT No HSCT
n=111 n=271
No. % No. % No. % No. %
None 826 93 3 2.7 138 50.9 967 76.2
At least 
one test
62 7 108 97.3 133 49.1 303 23.8
HBsAg 
only
35 3.9 63 57.1 60 22.1 158 12.44
HBs Abs 
only
5 0.6 0 3 1.1 8 0.63
HBsAg and 
Abs










7 0.8 19 17 16 5.9 42 3.3
Results 
A total of 1547 patients were initially assessed, 277 
were excluded from the study (221 were younger 
than 18, and 56 did not receive chemotherapy). 
The mean age was 56 (range 18 to 96) and 45.6% 
were males.888 out of 1270 (70%) patients had so-
lid organ malignancies, and the rest (382 or 30%) 
had hematologic malignancies, of whom 111 un-
derwent hematopoietic stem cell transplantation 
(HSCT) (Table 1). The majority were not screened 
Table 1.  General characteristics of the studied po-
pulation.
Descriptive statistics No. %
Age (mean, SD) 56.2 16.6
Gender (Female) 691 54.4




Leukemia, n (% among 
hematologic malignancies)
124 32.5
Lymphoma, n (% among 
hematologic malignancies)
182 47.7






Breast, n (% among solid 
malignancies)
304 34.2
Genitourinary, n (% among 
solid malignancies)
157 17.7
Gastrointestinal tract, n (% 
among solid malignancies)
148 16.7
Lung, n (% among solid 
malignancies)
119 13.4
Other2, n (% among solid 
malignancies)
160 18.0





Any test performed 303 23.9
HBsAg, HBs Abs, and anti HBc total Abs 42 3.3
SD: Standard deviation; HBV: Hepatitis B virus; HSCT: 
Hematopoietic stem cell transplant; 1: A plastic anemia, 
multiple myeloma, myelodysplastic syndromes; 
2: Adrenal carcinoma, central nervous system tumors, 
head and neck cancers, hepato-pancreato-biliary 
tumors, melanomas, sarcomas, thyroid tumors.
for hepatitis B (967 out of 1270 (76.1%). Only 3.3% 
(42) were screened with all of HBsAg, HBs Abs, and 
anti HBc total antibodies (7 in solid organ and 35 
in hematologic malignancies). 45 patients (3.5%) 
were tested for HBsAg and HBs Abs, and 50 pa-
tients (3.9%) tested for HBsAg and anti HBc total 
antibodies. A total of 303 patients (62 in solid ma-
lignancies, 241 in hematologic malignancies) were 
screened for any of the HBsAg, HBs Abs, or anti 
HBc total antibodies, and 158 (12.4%) were tested 
for HBsAg alone (Table 2). Among those who tes-
ted positive for any of the previously mentioned 
tests (in addition to HBeAg or anti HBeAbs) 20 
out of 25 were checked for HBV DNA. To further 
understand the factors associated with physician’s 
decision in performing appropriate HBV screening, 
we compared those who were appropriately scree-
ned to those who were not (Table 3). As shown in 
Table 3, patients who were appropriately screened 
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(42 patietns) were significantly younger (p=0.008) 
and were more likely to have hematologic malig-
nancy (n=35, 83.3%, p<0.0001) On multivariate 
analysis, having hematologic malignancy compared 
to solid malignancy was an independent predictor 
of performing appropriate screening (OR=11.87, 
95% CI [5.19-27.17], p<0.0001). Among patients 
who had hematologic malignancies, those who 
were appropriately screened (n=35) were younger 
in age (p=0.042) and had a history of HSCT (n=19, 
54.3%, p=0.001). on multivariate analysis, having 
a history of HSCT was an independent predictor of 
performing appropriate screening (OR=3.02, 95% 
CI [1.48-6.15], p=0.002).
Discussion
Although HBV screening rates have increased over 
time, as shown between 2002 and 2010 [22], a 
recent study performed in the United States has 
shown that screening before chemotherapy (with 
HBsAg and anti HBc Abs) was performed in only 
17% of cancer patients (excluding patients under-
going HSCT) [23]. Transplant specialists screened 
their patients most frequently (85%) compared to 
gastroenterologists who screened the least (34%) 
[24]. 
In the Middle East, very few studies assess HBV 
screening in adults prior to chemotherapy. And 
data on the rate or adequacy of screening remain 
scarce. National HBV screening programs that in-
clude patients who are planned for chemotherapy, 
or as part of the pre-transplant work-up, are being 
applied in Saudi Arabia and Jordan, but are not im-
plemented in Egypt, Pakistan, Qatar, Syria, Turkey 
or UAE [6, 25].
In fact, the Saudi Association for the Study of 
Liver diseases and Transplantation (SASLT) released 
practice guidelines in 2014 stating that HBV scree-
ning is indicated for all patients receiving immuno-
suppressive or chemotherapy (by testing for HBsAg, 
anti-HBs and anti-HBc antibodies) [26].
Our medical institution receives many high risk 
immunocompromised patients for further manage-
ment of their health conditions. The ever increa-
sing pool of bone marrow transplant patients and 
hematologic malignancies, as well as the growing 
number of patients receiving immunosuppressive 
medications, makes a strong case for HBV screening 
and evaluation of patients before starting them on 
long term immunosuppression. 
Our study demonstrated that the rate of adequa-
te screening is very low at our institution despite 
the initiatives and efforts to screen at risk indivi-
duals, manifested by testing for any of the serologic 
markers. Most of the patients who were screened 
were those who underwent HSCT considered to be 
at high risk of HBV reactivation compared to other 
patients [27]. Younger patients were also screened 
more frequently, despite the fact the prevalence of 
HBV has been shown to increase with age [28], and 
Table 3.  Comparing patients who were partially or 
not screened to patients with the appro-







Age (mean, SD) 49.5 (19.4) 56.4 (16.4) 0.008
Male 





n 24 555 
<0.0001
% 57.1 45.2







Age (mean, SD) 46.2 (18.9) 53.3 (20.3) 0.042
Male 





n 19 92 
<0.0001
% 54.3 26.5
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that viral reactivation could have more deleterious 
effects in older patients with potentially more co-
morbidities than younger adults.
The type of chemotherapy administered could 
not be assessed because of the small number of 
patients included. This could represent a limitation, 
along with the retrospective nature of the study. 
Despite all available recommendations, HBV scree-
ning remains suboptimal, and this places patients 
at risk of reactivation. Possible explanations include 
lack of established local guidelines and decreased 
awareness among physicians concerning the risk 
of HBV reactivation and its potential deleterious 
effects. Although some services such as The Bone 
Marrow Transplant Center at our center have HBV 
screening integrated into their pre-transplant pro-
tocol, many other services acknowledge the need 
for screening, yet they do not have an established 
policy for mandatory screening. This needs to be 
addressed and improved. 
Given the variability of recommendations and 
changing epidemiology and prevalence among va-
rious groups, this is the first study in Lebanon and 
the Middle East to assess the screening rates of 
HBV prior to chemotherapy and immunosuppres-
sant administration. This may help practicing physi-
cians from different specialties to standardize their 
practice, and protect their patients. The recent im-
plementation of the EPIC system at our institution 
can have a major impact on the quality of care of 
our patients by setting automatic reminders to phy-
sicians in order to screen 
patients prior to chemotherapy or other immuno-
suppressive medication, with the adequate recom-
mended serologic tests in a timely manner. 
Conclusion
Screening population at risk for HBV reactivation 
is still underperformed and not adequately done 
worldwide and in a leading tertiary care center in 
the Middle East. Improving awareness among phy-
sicians and patients, and implementing a protocoled 
approach can improve screening rates and therefore 
decrease the risk of viral reactivation in a vulnerable 
population, specifically with the increasing use of 
chemotherapy and immunosuppression. 
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